Global Adrenal Crisis Treatment Market Report and Forecast 2024-2032

Global Adrenal Crisis Treatment Market Outlook

The global adrenal crisis treatment market attained a value of USD 6.19 million in 2023. The market is estimated to grow at a CAGR of 5.5% and is expected to reach a value of USD 10 million by 2032. The market growth is expected to be driven by increased awareness about the importance of early diagnosis of congenital disorders.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Adrenal Crisis Insights

An adrenal crisis occurs when your adrenal glands do not produce enough of the hormone cortisol. It is a potentially fatal complication of adrenal insufficiency (Addison's disease). The adrenal glands are small and triangle-shaped and located just above each kidney. They produce hormones such as cortisol. Cortisol has an impact on nearly every organ and tissue in the body, some of its functions are as follows:

• Controlling the body's stress response

• Helping to regulate metabolism

• Inflammation suppression

• Blood pressure control

• Blood sugar control

• Controlling sleep-wake cycle

A lack of blood flow may result from an adrenal crisis (shock). Shock spreads quickly and can harm the organs. An adrenal crisis can kill up to 20% of people in shock, if not treated. Other threatening symptoms include seizures or coma.

The following are the most common symptoms of an adrenal crisis:

• Pain in the Abdomen or on the Side (Flank)

• Long-Lasting Fatigue

• Appetite Loss

• Skin Discoloration (Hyperpigmentation)

• Weakness

• Unknown Cause of Weight Loss

According to the global adrenal crisis treatment market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Break Up by Indication

• Primary

• Secondary

• Tertiary

Market Break Up by Diagnosis Method

• Blood Test

• ACTH Stimulation Test

• Insulin-induced Hypoglycemia Test

• Imaging Test

Market Break Up by Treatment Method

• Oral Cortisone
  • Hydrocortisone
  • Fludrocortisone Acetate
• Intravenous Injections
  • Corticosteroids
  • Saline Solution
  • Sugar (Dextrose)

Market by Treatment Channel

• Public

• Private

Market Break up Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Adrenal Crisis Epidemiology

Adrenaline crises are uncommon, about 42% of people with adrenal insufficiency will experience an adrenal crisis. Adrenal insufficiencies affect 1 in every 100,000 people in the United States.

Globally, primary adrenal insufficiency is estimated to affect 82-144 people per million, with autoimmunity being the most common cause in adults and genetic causes, particularly enzyme defects, being the most common cause in children. Secondary adrenal deficiency is estimated to affect 150-280 people per million. The most common cause is believed to be corticosteroid-induced insufficiency, even though the incidence of clinically relevant deficiency after glucocorticoid discontinuation is widely debated.

Adrenal Crisis Treatment Market Drivers

Increased awareness about the importance of early diagnosis of congenital disorders is expected to drive the adrenal insufficiency treatment market during the forecast period. Acquired adrenal insufficiency is expected to grow at a faster rate during the forecast period due to an increase in the risk of trauma cases caused by a variety of factors, such as road injuries, war-related trauma, other accidents, and an increase in global disease burden.

Because of drug treatment efficiency, there is a growing global demand for the development of newer and more technologically advanced products. As a result, major market players are investing in research and development programmes to develop new drugs.

Asia Pacific to Offer Investment Opportunities to the Global Investors

Improving healthcare infrastructure, rising awareness about the importance of timely diagnosis of underlying disorders such as adrenal insufficiency, and a large patient population are expected to present significant opportunities for the Asia Pacific adrenal crisis treatment market in the near future. Increased public and private healthcare spending in China and India are expected to attract manufacturers to these markets.

Therapeutic Landscape

At present, patients with adrenal insufficiency are given oral glucocorticoid replacement treatment, which does not exactly match the normal physiologic cortisol rhythm. Another novel method for treating adrenal insufficiency is continuous subcutaneous hydrocortisone infusion therapy, which is delivered via an insulin pump. During the forecast period, all of these factors are expected to drive the adrenal insufficiency market.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

• Takeda Pharmaceutical Company Limited

• Sandoz International GmbH

• Pfizer Inc

• Bristol-Myers Squibb Company

• Merck KGaA

• Antares Pharma

• Mallinckrodt Pharmaceuticals

• Mylan Pharmaceutical AG

• eTon Pharmaceuticals

Key Highlights of the Report